News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
365,057 Results
Type
Article (22689)
Company Profile (114)
Press Release (342254)
Multimedia
Podcasts (33)
Webinars (9)
Section
Business (120504)
Career Advice (1154)
Deals (20330)
Drug Delivery (74)
Drug Development (33910)
Employer Resources (144)
FDA (6295)
Job Trends (8435)
News (181951)
Policy (13255)
Tag
Academia (1616)
Academic (2)
Accelerated approval (3)
Adcomms (16)
Allergies (26)
Alliances (27140)
ALS (46)
Alzheimer's disease (760)
Antibody-drug conjugate (ADC) (69)
Approvals (6328)
Artificial intelligence (150)
Autoimmune disease (12)
Automation (10)
Bankruptcy (132)
Best Places to Work (6627)
BIOSECURE Act (12)
Biosimilars (55)
Biotechnology (78)
Bladder cancer (35)
Brain cancer (13)
Breast cancer (127)
Cancer (997)
Cardiovascular disease (90)
Career advice (1003)
Career pathing (32)
CAR-T (83)
Cell therapy (235)
Cervical cancer (9)
Clinical research (27181)
Collaboration (473)
Compensation (238)
Complete response letters (9)
COVID-19 (1115)
CRISPR (25)
C-suite (187)
Cystic fibrosis (54)
Data (1056)
Decentralized trials (1)
Denatured (21)
Depression (23)
Diabetes (113)
Diagnostics (3612)
Digital health (8)
Diversity (7)
Diversity, equity & inclusion (39)
Drug discovery (63)
Drug pricing (47)
Drug shortages (5)
Duchenne muscular dystrophy (49)
Earnings (47855)
Editorial (16)
Employer branding (23)
Employer resources (125)
Events (58892)
Executive appointments (545)
FDA (6863)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (5)
Funding (469)
Gene editing (49)
Generative AI (15)
Gene therapy (141)
GLP-1 (395)
Government (1589)
Guidances (37)
Healthcare (8704)
Huntington's disease (14)
IgA nephropathy (13)
Immunology and inflammation (38)
Indications (11)
Infectious disease (1181)
Inflammatory bowel disease (74)
Inflation Reduction Act (7)
Influenza (18)
Intellectual property (40)
Interviews (157)
IPO (9839)
IRA (16)
Job creations (2077)
Job search strategy (884)
Kidney cancer (8)
Labor market (35)
Layoffs (233)
Leadership (14)
Legal (3267)
Liver cancer (36)
Lung cancer (142)
Lymphoma (79)
Machine learning (1)
Management (45)
Manufacturing (154)
MASH (38)
Medical device (5805)
Medtech (5809)
Mergers & acquisitions (10861)
Metabolic disorders (326)
Multiple sclerosis (44)
NASH (14)
Neurodegenerative disease (34)
Neuropsychiatric disorders (5)
Neuroscience (1029)
NextGen: Class of 2025 (3251)
Non-profit (2146)
Now hiring (38)
Obesity (182)
Opinion (112)
Ovarian cancer (33)
Pain (41)
Pancreatic cancer (26)
Parkinson's disease (65)
Partnered (14)
Patents (73)
Patient recruitment (48)
Peanut (17)
People (39937)
Pharmaceutical (28)
Pharmacy benefit managers (2)
Phase I (8018)
Phase II (11491)
Phase III (10122)
Pipeline (764)
Policy (58)
Postmarket research (1070)
Preclinical (3811)
Press Release (71)
Prostate cancer (48)
Psychedelics (19)
Radiopharmaceuticals (143)
Rare diseases (176)
Real estate (3627)
Recruiting (56)
Regulatory (9266)
Reports (45)
Research institute (1394)
Resumes & cover letters (162)
Rett syndrome (4)
RNA editing (2)
RSV (26)
Schizophrenia (42)
Series A (86)
Series B (57)
Service/supplier (8)
Sickle cell disease (29)
Special edition (8)
Spinal muscular atrophy (75)
Sponsored (14)
Startups (2458)
State (1)
Stomach cancer (6)
Supply chain (29)
Tariffs (10)
The Weekly (11)
Vaccines (226)
Venture capitalists (30)
Weight loss (117)
Women's health (12)
Worklife (16)
Date
Today (39)
Last 7 days (461)
Last 30 days (1358)
Last 365 days (17398)
2025 (5781)
2024 (19285)
2023 (22385)
2022 (29001)
2021 (31427)
2020 (29330)
2019 (24123)
2018 (17949)
2017 (17372)
2016 (16667)
2015 (19760)
2014 (15397)
2013 (12626)
2012 (13647)
2011 (14231)
2010 (13794)
Location
Africa (439)
Alabama (26)
Alaska (5)
Arizona (111)
Arkansas (4)
Asia (19745)
Australia (3134)
California (3242)
Canada (1179)
China (202)
Colorado (143)
Connecticut (150)
Delaware (102)
Europe (45788)
Florida (466)
Georgia (78)
Hawaii (1)
Idaho (28)
Illinois (215)
India (19)
Indiana (204)
Iowa (8)
Japan (119)
Kansas (43)
Kentucky (15)
Louisiana (9)
Maine (45)
Maryland (363)
Massachusetts (2558)
Michigan (137)
Minnesota (226)
Mississippi (1)
Missouri (49)
Montana (17)
Nebraska (19)
Nevada (30)
New Hampshire (25)
New Jersey (958)
New Mexico (20)
New York (1009)
North Carolina (592)
North Dakota (8)
Northern California (1498)
Ohio (109)
Oklahoma (8)
Oregon (16)
Pennsylvania (594)
Puerto Rico (4)
Rhode Island (18)
South America (587)
South Carolina (11)
Southern California (1154)
Tennessee (62)
Texas (394)
United States (12208)
Utah (85)
Virginia (78)
Washington D.C. (30)
Washington State (273)
West Virginia (2)
Wisconsin (45)
365,057 Results for "apnea sciences corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
GLP-1
Lilly’s Zepbound Snags First Ever Sleep Apnea Drug Approval
The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in combination with diet and exercise.
December 23, 2024
·
2 min read
·
Kate Goodwin
Press Releases
Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives
A new survey conducted by Quantum Research Group, LLC finds that more than half of patients diagnosed with sleep apnea are not satisfied with their current treatment. Nearly 70 percent of patients express a willingness to switch to a prescribed pill-form treatment.
September 9, 2024
·
4 min read
Press Releases
Apnimed to Host Virtual Investor Event Highlighting the Potential for AD109 as a Novel Pharmacotherapy for Obstructive Sleep Apnea on April 11, 2025
March 26, 2025
·
6 min read
BioMidwest
Use of Tirzepatide Shown to Improve Sleep Apnea and Cardiovascular Outcomes
Findings from the SURMOUNT-OSA, a study of tirzepatide in patients with obstructive sleep apnea and obesity, were announced, revealing significant improvements in both sleep apnea severity and related metabolic issues.
June 21, 2024
·
4 min read
Press Releases
Wesper Revolutionizes GLP-1 Sleep Apnea Screening and Enables Personalized Treatment
February 12, 2025
·
3 min read
Government
Lilly Wins Medicare Coverage for Zepbound in Sleep Apnea
According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to secure CMS coverage for obesity drugs.
January 9, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Huxley Medical Announces FDA Clearance for Cellular-Enabled SANSA Home Sleep Apnea Test
February 5, 2025
·
3 min read
Press Releases
FDA Approves First Medication for Obstructive Sleep Apnea
December 23, 2024
·
4 min read
Press Releases
NAVER D2SF-Backed PranaQ® Receives FDA 510(k) Clearance for TipTraQ, an AI-Enabled Home Sleep Apnea Test
February 20, 2025
·
3 min read
Drug Development
Lilly Sees Path for Zepbound’s Label Expansion With Phase III Sleep Apnea Win
Data showed that Eli Lilly’s Zepbound could resolve obstructive sleep apnea in at least 43% of patients, solidifying the pharma’s case for label expansion.
June 24, 2024
·
2 min read
·
Tristan Manalac
1 of 36,506
Next
